slightbourne@noblecapitalmarkets.com, Author at Channelchek

Cocrystal Pharma (COCP) – 1Q25 Reported With Clinical Trial Milestone Updates

Posted on May 19, 2025May 19, 2025 by slightbourne@noblecapitalmarkets.com

Monday, May 19, 2025

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fourth Quarter Included New Data On Norovirus Variants. Cocrystal reported a 1Q25 loss of $2.3 million or $(0.23) per share. During the quarter the company announced Phase 1 results from its CDI-988 study in norovirus. Importantly, preclinical data showed efficacy against new norovirus variants. We believe this provides additional support to Cocrystal’s method of targeting highly-conserved viral replication enzymes to make effective drugs against both current and future variants. Cash on March 31, 2025 was $6.9 million.

CDI-988 Activity Includes New Variant Strains. CDI-988 is a protease inhibitor in development for norovirus and corona virus. CDI-988 has shown activity against multiple strains, with new preclinical data in April 2025 showing efficacy against the GII.17 and GII.4 strains that have recently been most prevalent. Results from the Phase 1 high-dose cohort in healthy subjects is expected to be announced in 2Q2025. A human challenge trial is planned for later in FY2025 to evaluate CDI-988 for treatment and prophylaxis against norovirus.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Bit Digital (BTBT) – Reports 1Q25 Results

Posted on May 19, 2025May 19, 2025 by slightbourne@noblecapitalmarkets.com

Monday, May 19, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q25 Overview. Bit Digital’s first quarter results were affected by mark-to-market losses on digital assets and lower bitcoin mining revenue, both of which reflected industry-wide headwinds and the strategic rebalancing of the business. The Company continued to make meaningful progress in scaling the infrastructure platform and diversifying revenue streams.

1Q25 Results. Revenue of $25.1 million was down 17% y-o-y as digital asset mining revenue fell 64%, while cloud services revenue jumped 84%. We were at $24.8 million. Driven by $49.3 million of mark-to-market losses on digital assets, Bit Digital reported a net loss of $57.7 million, or $0.32/sh, compared to a loss of $11.9 million, or $0.09/sh, last year. We projected a loss of $13.1 million, or $0.07/sh.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

30-Year Treasury Yield Tops 5% as Moody’s Downgrades U.S. Credit Rating

Posted on May 19, 2025May 19, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Moody’s downgrades U.S. credit rating from Aaa to Aa1, citing unsustainable debt and fiscal inaction.
– 30-year Treasury yield briefly rises above 5%, pressuring markets and borrowing costs.
– Investors question long-term safety of U.S. Treasurys as safe-haven assets.

The U.S. bond market was jolted Monday as yields on long-term Treasurys spiked following a downgrade of the nation’s credit rating by Moody’s Investors Service. The 30-year Treasury yield briefly topped 5.03% in early trading—levels not seen since late 2023—before retreating slightly as bond-buying resumed later in the session. The 10-year yield also climbed, reaching 4.497%, while the 2-year note edged close to 4%.

The market reaction came swiftly after Moody’s downgraded the U.S. credit rating from the top-tier Aaa to Aa1 on Friday, citing structural fiscal weaknesses and rising debt-servicing costs. The downgrade brings Moody’s in line with other major agencies like Fitch and S&P, which had already lowered their U.S. ratings in recent years.

“This one-notch downgrade reflects the increase over more than a decade in government debt and interest payment ratios to levels that are significantly higher than similarly rated sovereigns,” Moody’s said in its statement.

The move raised alarm bells on Wall Street and in Washington, as investors weighed the implications of higher yields on financial markets, consumer loans, and global confidence in U.S. fiscal management. Long-term Treasury yields directly influence rates on mortgages, auto loans, and credit cards—potentially tightening financial conditions for households and businesses.

Markets had already been uneasy following policy uncertainty in Washington. The latest trigger: a sweeping tax and spending bill backed by House Republicans and the Trump administration is advancing through Congress, raising concerns it will further balloon the deficit. Analysts estimate the legislation could add trillions to the debt over the next decade, worsening the very conditions that prompted Moody’s downgrade.

“This is a major symbolic move as Moody’s was the last of the big three rating agencies to keep the U.S. at the top rating,” Deutsche Bank analysts noted in a client memo. “It reinforces the narrative of long-term fiscal erosion.”

Moody’s also warned that neither party in Congress has offered a realistic plan to reverse the U.S.’s deficit trajectory, with high interest payments now compounding the debt burden. “We do not believe that material multi-year reductions in mandatory spending and deficits will result from current fiscal proposals,” the agency stated bluntly.

Meanwhile, investors are beginning to reevaluate the role of U.S. Treasurys as the world’s go-to safe-haven asset. The combination of mounting debt, political dysfunction, and now credit downgrades raises new questions about their long-term reliability.

While yields retreated slightly by midday as bargain hunters stepped in, the message from the market was clear: America’s fiscal credibility is under scrutiny, and investors are demanding higher compensation to lend long-term.

For small-cap and individual investors, rising yields can translate into greater borrowing costs, tighter capital access, and increased market volatility—all of which could ripple through equities in the weeks ahead.

Tech IPO Market Stirs Back to Life After Years of Drought

Posted on May 19, 2025May 19, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
IPO Market Rebounds: eToro and CoreWeave spark renewed tech IPO momentum.
Startups Move Ahead: Chime and Hinge Health revive public debut plans.
AI & Fintech Lead: These sectors drive the IPO resurgence despite market uncertainty.

After several years of stagnation, the tech IPO market is finally showing signs of revival. Recent successful listings from high-profile companies like eToro and CoreWeave, coupled with a growing pipeline of IPO-ready startups, have rekindled optimism among venture capitalists and retail investors alike.

Earlier this week, eToro, the social trading and brokerage platform based in Israel, made a striking debut on the Nasdaq. Its stock surged nearly 29% after pricing above the expected range—a strong signal that investor appetite for new tech listings may be returning. The timing was crucial. Just weeks ago, uncertainty stemming from President Trump’s abrupt tariff policy had cast a shadow over the broader market and cooled IPO ambitions.

Adding further momentum, CoreWeave, an AI infrastructure company, posted a remarkable 420% revenue increase in its first earnings report since going public in March. The company’s stock has more than doubled in value since its IPO, reflecting sustained investor enthusiasm for artificial intelligence and cloud infrastructure plays. According to PitchBook and the National Venture Capital Association, nearly 40% of Q1 venture capital exit value came from CoreWeave’s listing alone.

This rebound, however, comes after a long dry spell. Since early 2022, startups across fintech, health tech, and enterprise software have largely stayed private, waiting for more favorable conditions. The brief optimism earlier this year was quickly dampened when the Trump administration’s surprise tariff announcement in April rattled the markets. In response, companies like Klarna and StubHub shelved their IPO plans.

But with the administration now pausing its most aggressive tariff measures for 90 days, confidence is starting to return. Fintech company Chime filed its IPO prospectus this week, having delayed its plans due to the earlier tariff-driven volatility. Similarly, digital health firm Omada Health submitted its filing last week.

Next week, all eyes will be on Hinge Health, a virtual physical therapy platform. The company updated its IPO filing with a pricing range of $28–$32, potentially valuing it at $2.4 billion. This offering will be an important litmus test for investor sentiment toward the digital health sector, which boomed during the pandemic but has since seen growth slow.

Meanwhile, Cerebras, a chipmaker focused on AI hardware, has finally cleared regulatory hurdles and is preparing to go public later this year. The move reflects strong demand in the AI space, even as regulatory and geopolitical risks linger.

There are also notable shifts in the digital asset space. Galaxy Digital, originally listed in Canada due to U.S. regulatory hesitance toward crypto, has now moved its shares to the Nasdaq in a bid to access a broader investor base.

Despite these encouraging signs, experts remain cautious. Ernst & Young’s Rachel Gerring believes the IPO market is “trending in the right direction,” but warns that volatility and geopolitical risks could still stall momentum. Many startups are being advised to focus on readiness rather than timing, ensuring they can launch when conditions are ideal.

For now, the market is showing signs of life. But whether this marks the start of a sustained comeback or another false dawn remains to be seen.

Wall Street’s CEO: Jamie Dimon’s Potential Exit Worries Investors as JPMorgan Dominates

Posted on May 16, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Jamie Dimon’s run as CEO of JPMorgan Chase is nearing its conclusion, but the financial world is far from ready to say goodbye. At 69, Dimon is arguably more powerful than ever—commanding both respect on Wall Street and influence in Washington—and investors are beginning to confront the reality of his eventual departure with concern.

“He has more public clout than he’s ever had before in his life,” said Wells Fargo analyst Mike Mayo, reflecting the broad sentiment that Dimon’s role as JPMorgan’s leader is a stabilizing force in a volatile financial landscape. “And that clout comes hand in hand with his position at JPMorgan.”

That position, which Dimon has held since 2006, has led JPMorgan to unparalleled success. Under his leadership, the bank has delivered a median 20% annual return to shareholders—eclipsing both the S&P 500 and its banking peers. The firm is also operating with greater efficiency than its rivals, spending just $0.51 for every $1 of revenue compared to $0.63 or more for competitors like Goldman Sachs and Citigroup.

As JPMorgan prepares for its annual Investor Day on Monday, speculation around Dimon’s retirement will be front and center. Though he hinted last year that his retirement was within five years, and more recently confirmed that the “base case” is just a few years away, there has been no formal timeline announced. The ambiguity has only deepened investor anxiety.

The succession question is now the “single biggest idiosyncratic risk factor” for JPMorgan’s stock, according to Bank of America analyst Ebrahim Poonawala. Among the top internal contenders are consumer banking chief Marianne Lake and CFO Jeremy Barnum, but few expect any successor to fill Dimon’s shoes easily.

What makes Dimon’s potential exit especially consequential is his influence beyond finance. In 2025, his public comments on recession risks and trade policy made headlines and—according to media reports—even influenced President Trump’s decision to pause tariffs on Chinese goods. Trump referred to Dimon as “very smart” and acknowledged watching his interviews.

Despite Dimon’s downplaying of his sway in Washington, it’s clear his voice carries weight. He has urged more diplomacy with China and advocated for giving Treasury Secretary Scott Bessent space to lead trade talks. His words, in some cases, have moved markets.

And JPMorgan’s strategic position remains strong. The firm has invested over $17 billion in technology and maintains over $50 billion in excess capital, giving it ample room for growth through lending, acquisitions, or shareholder returns.

Shareholders like Mindee Wasserman, who holds over 1,000 JPM shares, are hoping he stays at least until the next election. “If he stays as long as he wants, that would be fine,” she said. “I would certainly hope he doesn’t leave before the next election.”

For now, Wall Street waits—and hopes Dimon isn’t going anywhere just yet.

Zomedica (ZOMDF) – Restructuring Begins To Bear Fruit In 1Q25

Posted on May 16, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Friday, May 16, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q25 Showed Expected Year-Over-Year Growth. Zomedica reported 1Q25 loss of $63.9 million or $(0.07) per share, including an Impairment Expense of $55.8 million related to the company’s lower market capitalization and stock price. Excluding this charge, Net Loss would have been about $8.0 million. Revenues of $6.5 million showed an annual increase of 3.8% over 1Q24. As expected, there was a seasonal decline from 4Q24 due to the year-end effect on equipment spending. Cash and equivalents on March 31, 2025 were $64.6 million.

Product Mix Reflects Growing User Base. During the quarter, Consumables increased to 70% of sales with Capital Equipment at 30% of sales. This shifting product mix reflects an increasing total number of instruments in use and more assay offerings to increase utilization of each instrument. We expect the consumable segment to continue its growth as additional capital equipment sales add to the user base and introduction of new assays increases the number of tests run on each instrument.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Bitcoin Depot (BTM) – Q1 Results Exceed on Revenue and Margin Strength

Posted on May 16, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Friday, May 16, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Q1 results. The company reported 18.5% revenue growth in Q1 to $164.2 million, better than our estimate of $151.0 million. Adj. EBITDA was $20.3 million, significantly better than our estimate of $12.8 million, on the back of strong 20% gross margins (our estimate was 17%).

Ramping in Internationally. Management highlighted that the company deployed roughly 150 kiosks in Australia to date, with approximately 150 additional kiosks ready for deployment. Moreover, the company is evaluating at least 2 additional countries for potential expansion later in 2025.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

China Holds Back Key Rare Earths Despite Easing Other U.S. Export Curbs

Posted on May 16, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– China lifts some trade curbs on 28 U.S. firms, but keeps rare earth metals off the table
– Export ban on 7 critical rare earth elements remains intact
– Dual-use export restrictions paused for 90 days amid renewed U.S.-China diplomacy
– Defense, energy, and EV sectors in U.S. remain exposed to supply risks

In a carefully calculated move, China announced on Thursday a temporary suspension of some trade restrictions targeting 28 American firms—but stopped short of lifting its export ban on seven critical rare earth elements, underscoring its ongoing strategic leverage over the United States.

The easing of some non-tariff measures comes just days after high-level trade talks in Geneva, where U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng appeared together in a rare public show of diplomatic engagement. But while China’s Commerce Ministry agreed to suspend dual-use export curbs and temporarily removed 17 companies from its “unreliable entity list,” it retained export controls on key minerals like dysprosium, terbium, and yttrium—materials vital for U.S. defense and clean energy production.

The seven rare earths still restricted—samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium—are central to everything from guided missiles to EV motors. According to analysts, this deliberate exclusion signals Beijing’s intent to maintain strategic pressure even as it opens the door to limited cooperation.

“This is China drawing a line in the sand,” said one Asia-based commodities analyst. “They’re signaling flexibility on diplomacy, but the core leverage—rare earth dominance—is not being sacrificed.”

The freeze on rare earth exports was initially introduced in early April as part of China’s retaliation against President Trump’s sweeping “Liberation Day” tariffs. That package included export licensing controls for the seven elements and the addition of several U.S. defense-adjacent companies to blacklists. While some of those companies, including Teledyne Brown Engineering and Kratos Unmanned Aerial Systems, received a 90-day reprieve, the rare earths ban remains firmly in place.

Notably, China’s Commerce Ministry released a parallel statement this week emphasizing the need for stronger national security oversight of its rare earth industry, including measures to combat smuggling and tighten internal supply chain controls. This was reinforced by state-linked social media accounts hinting at the metals’ impact on U.S. military readiness.

The U.S. currently sources over 70% of its rare earth imports from China, a vulnerability that has become more politically charged amid renewed trade hostilities. American efforts to diversify rare earth supply chains—such as investing in Australian mining firms or restarting domestic refining—remain years from full-scale viability.

For investors, the bifurcated approach by China suggests that while the broader trade environment may be softening temporarily, core strategic resources like rare earths are unlikely to be freely accessible in the near term. Defense contractors, energy manufacturers, and EV suppliers will continue to face uncertainty, potentially pushing up costs and driving supply chain shifts.

Until rare earth independence becomes a reality, this remains a pressure point Beijing is unlikely to relinquish.

Take a moment to take a look at more emerging growth natural resources companies by taking a look at Noble Capital Markets’ Research Analyst Mark Reichman’s coverage list.

DICK’S Sporting Goods to Acquire Foot Locker in $2.5B Deal, Creating Sports Retail Powerhouse

Posted on May 15, 2025May 15, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– DICK’S to acquire Foot Locker for $2.4B equity value, $2.5B enterprise value
– Combined company to operate globally across 20+ countries
– Deal expected to be accretive to earnings and unlock $100M–$125M in cost synergies
– Foot Locker to remain a standalone brand under the DICK’S portfolio

In a bold move set to reshape the global sports retail landscape, DICK’S Sporting Goods announced plans to acquire Foot Locker in a transaction valued at approximately $2.5 billion. The deal, expected to close in the second half of 2025, creates a retail giant capable of reaching a broader demographic—from performance-driven athletes to sneaker culture enthusiasts—across more than 20 countries.

Under the terms of the agreement, Foot Locker shareholders will have the option to receive either $24 per share in cash or 0.1168 shares of DICK’S common stock for each Foot Locker share. This represents a premium of 66% over Foot Locker’s recent 60-day volume-weighted average price. The acquisition multiple stands at roughly 6.1x Foot Locker’s 2024 adjusted EBITDA.

The merger significantly expands DICK’S international footprint while preserving Foot Locker’s brand identity. DICK’S plans to operate Foot Locker as a standalone business unit, retaining its portfolio of popular sub-brands like Champs Sports, Kids Foot Locker, WSS, and atmos. Combined, the companies will operate over 3,200 stores and generate nearly $20 billion in annual revenue.

For investors, this acquisition represents a strategic play to unlock long-term value through scale and operational efficiency. DICK’S expects the deal to be accretive to earnings in the first full fiscal year following the close—excluding one-time costs—and estimates $100–$125 million in medium-term cost synergies. These savings are projected to come from procurement, direct sourcing, and supply chain optimization.

The move also marks DICK’S entry into international markets and builds on its successful House of Sport concept by leveraging Foot Locker’s expertise in sneaker culture. The combined company will cater to a more diverse consumer base with differentiated store concepts and enhanced digital experiences.

Leadership at both companies highlighted the strategic and cultural alignment behind the deal. DICK’S Executive Chairman Ed Stack emphasized Foot Locker’s brand equity and cultural relevance, while CEO Lauren Hobart noted that the merger creates a new global platform for sports and sneaker culture.

Foot Locker CEO Mary Dillon framed the acquisition as a natural evolution of the brand’s mission and a value-creating opportunity for shareholders, giving them the choice between immediate liquidity and future growth participation.

The transaction will be financed through a combination of cash-on-hand and new debt, with Goldman Sachs providing committed bridge financing. Regulatory approval and a shareholder vote are the final hurdles, with no major obstacles expected.

For small-cap investors, this deal has wide implications. While neither DICK’S nor Foot Locker are in the small-cap bracket themselves, the merger sends a strong signal that retail consolidation is accelerating. The competitive pressures and strategic partnerships that follow could impact suppliers, regional chains, and logistics companies that serve the growing global sports retail ecosystem.

Unicycive Therapeutics (UNCY) – 1Q25 Reported As OLC PDUFA Date Approaches

Posted on May 15, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, May 15, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Counting Down To The OLC PDUFA Date. Unicycive reported a 1Q25 loss of $21.2 million or $(0.61) per share, consistent with our estimates. We continue to expect approval of OLC (oxylanthanum carbonate) around its PDUFA date of June 28, followed by its launch later in the year. The company had $19.8 million in cash on March 31, 2025.

OLC Reduces Pill Burden To Improve Compliance. OLC is Unicycive proprietary formulation of lanthanum carbonate. It was developed to reduce serum phosphate levels in renal dialysis patients with only two small pills per day. We expect OLC to compete against Fosrenol (from Shire), the approved formulation of lanthanum, that requires chewing 3 to 6 large pills each day. This difference makes patient compliance easier.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

SKYX Platforms (SKYX) – U.S. Partnership and Automation Bolster Production Agility

Posted on May 15, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, May 15, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 results. The company reported Q1 revenue of $20.1 million, in line with our estimate of $20.4 million. An adj. EBITDA loss of $3.6 million was also largely in line with our loss estimate of $3.4 million.

Flexible production capabilities. In response to recent tariff-related uncertainty, the company established a partnership with U.S.-based Profab Electronics, enhancing its production flexibility. While elevated tariffs remain a policy risk, recent pauses have mitigated any near-term disruption to the company’s production partnerships in Southeast Asia.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Sky Harbour Group (SKYH) – Leasing Momentum Drives Favorable Revenue Cadence

Posted on May 15, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, May 15, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 results. The company reported Q1 revenue of $5.6 million, better than our estimate of $5.1 million. An adj. EBITDA loss of $3.3 million was roughly in line with our estimate of a loss of $3.4 million.

New campuses leasing up. Notably, the company’s new campus at Phoenix Deerfield Airport (DVT) welcomed its first tenants, while Dallas (ADS) and Denver (APA) are also in the phase 1 lease-up process and should welcome tenants within weeks. The continued lease up of these three campuses is expected to be a significant driver of sequential revenue improvement throughout the balance of the year.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Snail (SNAL) – Off To A Good Start

Posted on May 15, 2025May 16, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, May 15, 2025

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q1 results. The company reported Q1 revenue of $20.1 million and an adj. EBITDA loss of $3.3 million, both of which were better than estimates of $18.0 million and a loss of $4.5 million, respectively. Notably, revenue increased 42.5% over the prior year period and was driven by ARK Ultimate Mobile Edition, released in December 2024, and less deferred revenue associated with ARK: Survival Ascended sales.

Favorable outlook. The company has several releases slated for 2025, including a 10th-anniversary expansion pack for ARK: Survival Evolved, the release of Bellwright on Xbox in Q4, and new content for Ark: Ultimate Mobile Edition. Additionally, the company is releasing nine new titles in 2025, including Robots at Midnight, Honeycomb, and Echoes of Elysium, which could have breakout potential. We view the company’s efforts to drive user engagement and diversify revenue streams favorably

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).